Objective: The Child and Adolescent First-Episode Psychosis Study is a longitudinal study of early-onset first psychotic episodes. This report describes the naturalistic psychopharmacological treatment administered during a 24-month follow-up period, as well as discontinuation rates, reasons for discontinuation, and adverse effects.
S tudies comparing different antipsychotics in patients with early-onset psychotic disorders suggest that there are no significant differences in effectiveness between first-generation and second-generation antipsychotics or when comparing different second-generation antipsychotics. 1Y5 As far as adverse effects are concerned, all second-generation antipsychotics are associated with potentially significant weight gain, 6 with olanzapine presenting the highest values.
1Y3 Short-term studies have found significant differences in neurological adverse effects subscales and extrapyramidal symptoms, which are more frequent with risperidone than with olanzapine. 2, 4 As for clozapine, open studies in children and adolescents with psychotic disorders resistant to other antipsychotics 7Y10 have reported good response for both positive and negative symptoms.
Many questions regarding the efficacy, effectiveness, and safety of antipsychotic treatments in psychotic disorders in children and adolescents remain to be answered. The number of short-term controlled studies in children and adolescents has increased, but most of them last no longer than 3 to 12 weeks. In recent years, several longer clinical trials of the treatment of psychotic disorders in children and adolescents have been published. In the study of Arango et al 1 of 50 adolescents randomized to olanzapine or quetiapine for 6 months, both treatments reduced psychotic symptoms, but olanzapine patients gained more weight. Findling et al 11 investigated early-onset schizophrenia spectrum disorder in a randomized controlled study (the TEOSS [Treatment of Early-Onset Schizophrenia Spectrum]) lasting 44 weeks with olanzapine, risperidone, and molindone in 54 patients in the maintenance phase. No agent demonstrated greater efficacy, and discontinuation rates did not differ significantly between the treatment groups; adverse events were the most common reason for discontinuation. Naturalistic studies in children and adolescents are also limited; some 6-month studies have been published, 2, 12 but only 1 recent study 13 had a duration longer than 12 months. The differences in the definition of discontinuation, which included the drugs administered during follow-up, not only the initial antipsychotic treatment, make the results difficult to interpret. In adults, several large, long-term naturalistic studies 14Y17 have analyzed discontinuation rates in antipsychotic treatment, finding lower rates with second-generation antipsychotics such as olanzapine, clozapine, and risperidone than with first-generation agents.
14 Among second-generation antipsychotics, olanzapine showed lower rates of discontinuation in controlled 18 and observational studies.
14Y17
The Child and Adolescent First-Episode Psychosis Study (CAFEPS) is a multicenter, longitudinal follow-up study designed to assess clinical characteristics and psychopharmacological treatment in the first 2 years after a psychotic episode. The present report describes the naturalistic psychopharmacological treatment administered during 2 years of follow-up, as well as discontinuation rates, the most common reasons for treatment changes, and adverse effects. We expected to find high discontinuation rates of the initial antipsychotic treatment. We also expected that the various antipsychotic treatments would present similarities in the discontinuation rates but differences in the reasons for change and tolerability profiles, such as more extrapyramidal symptoms with risperidone and more weight gain with olanzapine.
METHODS

Subjects
Subjects were patients entering the CAFEPS recruited between March 2003 and November 2005 from child and adolescent psychiatry units at several Spanish university hospitals. All patients who were seen at these facilities during the 2-year recruitment period and who met the inclusion criteria were invited to participate in the CAFEPS. The final sample comprised 110 children and adolescents.
Inclusion criteria were age between 7 and 17 years at the time of initial evaluation and the presence of positive psychotic symptoms (within a psychotic episode) such as delusions or hallucinations of less than 6 months' duration. This short duration of positive psychotic symptoms was established to increase the homogeneity of the sample and to avoid the influence of variables such as prolonged psychopharmacological treatment or extended admission periods. The diagnosis of schizophrenia may be made based on negative or affective symptoms of more than 6 months' duration. Exclusion criteria were presence of a concomitant Axis I disorder at the time of evaluation that might account for the psychotic symptoms (for instance, substance abuse, autism spectrum disorders, posttraumatic stress disorder, or acute stress disorder), mental retardation according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria including not only an IQ below 70 but also impaired functioning, pervasive developmental disorder, neurological disorders, history of head trauma with loss of consciousness, and pregnancy. Occasional substance use was not an exclusion criterion if positive symptoms persisted for more than 2 weeks after a negative urine drug test. A complete description of the methodology and recruitment criteria has been provided elsewhere. 19 
Procedure
A complete evaluation was performed with a structured diagnosis interview and assessment of clinical scales at baseline and after 24 months of treatment and follow-up. The participants were assigned to various treatment arms according to the treatment they were receiving at the time of enrollment (n = 56). The remaining patients were drug naBve, and the decision to initiate treatment was taken by the physician. Psychopharmacological treatment and the reasons for change were recorded at baseline and after 6, 12, and 24 months of treatment and follow-up. The Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale was also administered after 6, 12, and 24 months. Weight measurements included weight in kilograms, body mass index (BMI) in kilograms per meter squared, and BMI z score (BMI values adjusted for age and sex using conversion to a z score with Spanish normative charts 20 to correct for the known BMI variation according to these parameters).
Diagnostic Interview
The diagnosis was established according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (American Psychiatric Association) criteria using the Spanish version 21 of the K-SADS-PL (Kiddie-Schedule for Affective Disorders and SchizophreniaYPresent and Lifetime version), a semistructured diagnostic interview designed to assess current and past psychopathology. The K-SADS-PL was administered both at baseline and at 24 months of follow-up. Parents and patients were interviewed separately by psychiatrists trained in the use of the instrument in children and adolescents.
Assessment Scales
The Positive and Negative Symptom Scale (PANSS) in its validated Spanish version 22 assesses psychopathological symptoms of schizophrenia. This version comprises the total scale score of 30 items and 3 subscales (positive symptoms, negative symptoms, and general psychopathology). The Clinical Global Impression Scale 23 was used to assess severity and improvement of global symptoms on a scale of 1 to 7, and the Global Assessment of Functioning Scale 24 was used to measure the severity of symptomatic and psychosocial functioning on a scale from 1 to 100. Socioeconomic status was estimated with the Hollingshead Redlich Scale. 25 The UKU Scale, 26 a comprehensive rating scale, was administered to assess the general adverse effects of psychotropic drugs.
Data Analysis
The main measure and aim of the study were the discontinuation of initial treatment. The study also included the antipsychotic treatment changes made as well as the reasons for these treatment modifications between baseline and 6, 12, and 24 months. Discontinuation of treatment was defined as (1) stopping antipsychotic medication initiated at the beginning of the study, (2) addition of other antipsychotic medication, or (3) switch to another antipsychotic. The reasons for discontinuation of initial treatment were defined as insufficient response, adverse reactions, and others, which included causes such as disagreement with psychopharmacological treatment. Clinical improvement was also registered, but it was not included in the calculation of the discontinuation rate because of the positive quality it attaches to treatment in contrast to other reasons for change.
For descriptive purposes, continuous variables were expressed as means and SD; ordinal variables were expressed as medians and interquartile range, and dichotomous variables were expressed as absolute frequencies and percentages. We used analysis of variance (ANOVA) on ranks test to compare the means of more than 2 groups or the ANOVA/analysis of covariance when the distribution was shown to be normal by the Kolmogorov-Smirnov test. In the same conditions, we used the Mann-Whitney U or Student t test to compare the means of 2 groups. We used the least significant difference (LSD) to perform the multiple comparisons between the principal treatment groups when any statistical difference existed. The Fisher exact test was used to compare percentages of the dichotomous variables with small expected frequencies. All tests were 2-tailed, and differences of P G 0.05 were considered significant. Statistical analyses were carried out with the Statistical Package for the Social Sciences, version 15.0 (SPSS Inc, Chicago, IL).
RESULTS
Sociodemographic and Clinical Characteristics of the Sample
Demographic and clinical details of the largest treatment groups are summarized in Table 1 . Of the 110 initial patients, 8 patients dropped out from the study before 6 months, 15 patients before 12 months, and 12 patients between 12 and 24 months; thus, 83 patients remained in follow-up until 24 months. Attrition was due to refusal to collaborate in the study (n = 14), loss of contact with the patient (n = 7), and other reasons such as change of residence (n = 6). At baseline, without counting tobacco use (n = 34, 30.9%), 37 patients (33.6%) were taking substances: 21 patients (19%) only cannabis, 11 (9%) cannabis and other drugs (cocaine, amphetamines, lysergic acid diethylamide), 5 (4.5%) only alcohol, and 1 patient (0.9%) alcohol and lysergic acid diethylamide. There were no significant differences in the main clinical baseline variables and initial treatment between the dropouts and follow-up completers at 6, 12, and 24 months.
Diagnoses at baseline were schizophrenia (n = 8), schizoaffective disorder (n = 5), schizophreniform disorder (n = 30), psychotic disorder not otherwise specified (n = 42), major depressive disorder with psychotic symptoms (n = 12), and bipolar disorder (n = 13). At 24 months, the diagnoses of the 83 patients in follow-up were schizophrenia (n = 43), schizoaffective disorder (n = 5), psychotic disorder not otherwise specified (n = 5), major depressive disorder with psychotic symptoms (n = 4), and bipolar disorder (n = 19). Seven patients no longer met criteria for a psychiatric diagnosis. No significant differences were found in the distribution of diagnoses between the main treatment groups.
The 110 patients were classified as follows according to initial antipsychotic treatment: olanzapine (n = 18), risperidone (n = 51), quetiapine (n = 16), combined antipsychotic (n = 16), Table 4 shows the groups' distribution and median doses at 6, 12, and 24 months. Table 2 shows the changes in antipsychotic administration between the initial treatment and follow-up. The most frequent change was from one second-generation antipsychotic to another. Percentages of discontinuation at 6, 12, and 24 months of treatment are shown in Table 3 . No significant differences were found between different treatments at any time point. Time to discontinuation for the main antipsychotic groups is displayed in Figure 1 . All treatment groups presented the highest discontinuation rates during the first 6 months, when an overall discontinuation rate of 44.5% was observed, increasing by 14.6% to a total of 59.1% at 12 months. From 12 months onward, the increase in the discontinuation rate was lower, increasing by 11.8% to the final overall rate of 70.9%. Table 3 shows different reasons for discontinuation at 6, 12, and 24 months. Insufficient response was the main reason for discontinuation at all time points, and no significant differences were found between treatment groups regarding the type of reason (insufficient response, adverse reaction, or other) or the type of discontinuation (stop, addition, or switch).
Treatment Discontinuation and Reasons for Discontinuation
No significant differences were found in discontinuation rates according to age group and sex at any time. As regards reasons for discontinuation, significant differences were found at 12 months for sex and for insufficient response (P = 0.039), which were higher in males, but no differences were found for sex at the other time points and none for age group at any point in the follow-up. Table 4 shows BMI, BMI increase, BMI z score, BMI z score increase, and mean score on the different UKU subscales in medication groups at 6, 12, and 24 months. At 6 months, significant differences were found in BMI increase and BMI z score increase, which were higher in olanzapine than in risperidone and quetiapine. Significant differences were also found in neurological adverse effects, which were most frequent in the risperidone group. At 12 and 24 months, there were no significant differences between the different drugs.
Weight Increase and Other Adverse Effects
No significant differences were found in UKU scale scores for age or sex at any point in the follow-up. Age was not significantly correlated with BMI increase, but significant differences were found between sex and BMI increase adjusted for baseline values: males presented a mean increase of 3.77 (confidence interval, 2.687Y4.853) and females a mean increase of 1.34 (confidence interval, j0.263 to 2.951), the difference being significant (P = 0.015).
Combined Antipsychotics and Other Antipsychotics Groups
Sixteen patients were initially treated with combined antipsychotics. At 6 months, the number of patients receiving an antipsychotic combination had decreased markedly (n = 3). At 12 and 24 months, this group consisted of patients from different treatment groups, whereas patients who initially received combination had been switched to monotherapy (Table 2) . The other antipsychotics group comprised mainly aripiprazole, ziprasidone, and a minority of typical antipsychotics. The baseline group grew progressively in the first 12 months from 6 patients at baseline (2 on haloperidol, 2 on aripiprazole, and 2 on ziprasidone) to 11 at 12 months (6 on aripiprazole, 4 on ziprasidone, and 1 patient on chlorpromazine), but fell to 7 patients at 24 months (4 on aripiprazole, 1 on ziprasidone, 1 on haloperidol, and 1 patient on chlorpromazine). At all time points, the most frequent cause of discontinuation was insufficient response (Table 3) .
Clozapine
At baseline, none of the patients were treated with clozapine, but at 6 months, the clozapine group comprised 6 patients, increasing at 8 at 12 months, most of them in combination with other antipsychotic treatment. At 24 months, the group still comprised 8 patients: 6 in monotherapy and only 2 in combination. Table 4 shows median doses and adverse effects compared with the main treatment groups. At 12 and 24 months, there were no significant differences in BMI, BMI increase, BMI z score, or BMI z score increase. As for UKU scale scores, significant differences were found between clozapine and the other antipsychotics on the autonomic subscale at 12 and 24 months. No significant differences were observed on the other subscales or in the total score. At 12 months, most of the patients receiving clozapine were also taking another antipsychotic. Comparing the subgroup of patients treated with clozapine in monotherapy (n = 6) with olanzapine, risperidone, and quetiapine group at 24 months, the differences in the autonomic subscale remained significant. No patients presented serious hematologic adverse effects during the 24 months of follow-up.
DISCUSSION
The main finding of the present study is that overall antipsychotic discontinuation in children and adolescents for reasons other than clinical improvement was 59.1% after 12 months of follow-up and 70.9% after 24 months; no significant differences were found between the treatment groups. Because of the lack of long-term naturalistic studies in children and adolescents, the only study we can use as a reference point is the TEOSS. 11 In that study, treatment was also adapted according to clinical improvement and weight gain. Our discontinuation rate at 12 months is lower than that observed by Findling et al, 11 who reported a rate of 74% at 44 weeks. As in our study, no significant differences were found between treatments at 12 months even though olanzapine showed the highest discontinuation rate. The higher rates of discontinuation observed in the TEOSS may be a consequence of the study design, as controlled studies tend to have more restrictions even in open follow-up. At 24 months, 70.9% of our patients had discontinued the antipsychotic treatment initiated at baseline. Our data can only be compared with long-term naturalistic studies in adults applying a similar method at 36 months of follow-up, in which discontinuation rates were between 60% and 80% and remained constant over time. 15Y17 In the present study, all treatment groups presented the highest discontinuation rates during the first 6 months; after completing 12 months with the same antipsychotic treatment, discontinuation increased at a much slower rate, increasing only by 11.8% at 24 months. In child and adolescent first psychotic episodes, it is probably during the first year that most changes in treatment occur; when the treatment has been adapted by the clinician after assessing tolerability and clinical improvement, it tends to be maintained for longer than that in adults. 27 Of course, in children and adolescents, compliance with psychopharmacological treatment and the regular performance of clinical controls are supervised by parents, which this may facilitate adherence to treatment compared with adults. Adult studies comparing atypical antipsychotics showed lower discontinuation rates for olanzapine. 15, 17, 18 In our study, olanzapine showed slightly higher discontinuation rates at 6, 12, and 24 months, although the differences were not statistically significant. These differences in discontinuation rates between adult and child studies may be due to the higher weight gain in children and adolescents treated with second-generation antipsychotics than in adults, 6 especially in the case of olanzapine. 28 Comparing treatment tolerability in the 3 main pharmacological groups at 6 months, significant differences were found in BMI increase and BMI z score increase with olanzapine and in neurological effects with risperidone. Short-term studies with children and adolescents found similar results for olanzapine 1Y5,28 and risperidone. 2, 4 At 12 and 24 months, no significant differences were found, probably because of the naturalistic design; by that time, subjects with significant adverse effects have changed treatment. At 12 months, the results are similar to those of the TEOSS at 52 weeks, in which the weight gain was significant in each medication arm, but no significant differences were found between groups.
The main reason for discontinuation at any point was insufficient response, followed by adverse reactions. Conversely, in the TEOSS study, the main reason was adverse reactions, followed by insufficient response. We stress the possible influence in these percentages of the study design: in controlled trials, the definition of insufficient response and adverse reactions is determined by strict criteria, but in naturalistic studies the definition is probably less precise. This may have increased the percentage of insufficient response in our study, because changes in medication in clinical practice may have been introduced more rapidly to accelerate patient improvement. Another relevant is the fact that psychotic disorders during childhood and adolescence often have a more severe presentation than in the adult-onset form. This severity may determinate a treatmentrefractory course 29 which may favor treatment discontinuation. After 3 years of follow-up in a long-term naturalistic study in adults, Haro et al 15 also reported inadequate response as the main reason for discontinuation, with olanzapine recording the highest percentage.
The small sample size does not allow statistical comparison of the results of the remaining antipsychotic groups studied. In the initial combined antipsychotic group, there was a clear trend toward monotherapy at 24 months, which is always recommended to minimize adverse effects. 30 In the other antipsychotics group, the sample was recruited between 2003 and 2005, when risperidone, quetiapine, and olanzapine were frequently used in children and adolescents, but since that time, new antipsychotic treatments such as aripiprazole have been successfully introduced and have proved effective in acute treatment in adolescents with schizophrenia. 31 Clinical experience with clozapine in children and adolescents is limited. This drug is used less frequently in this setting, being indicated in cases of resistant schizophrenia; it may have serious adverse effects such as blood dyscrasia, and so our results regarding its maintenance rate are of interest. At 12 months, 8 patients were receiving this treatment, most of them in combination with another antipsychotic, but at 24 months all of them remained in treatment with clozapine. Similar results have been observed in long-term naturalistic studies in adults, 16, 17 where higher maintenance rates were observed in the clozapine group than in the groups receiving other antipsychotics such as risperidone, olanzapine, and quetiapine. Significant differences on the autonomic subscale of the UKU were found between clozapine, risperidone, and olanzapine; most patients in the clozapine group at 12 months were receiving combined treatment with another antipsychotic, and so adverse effects could have been due to either treatment. Nevertheless, at 24 months, most patients were in monotherapy, and significant differences remained on the autonomic subscale of the UKU. No significant differences were found in either BMI or BMI increase. No cases of serious hematologic adverse effects after 24 months of follow-up were observed, indicating that clozapine tolerability was quite similar to that of other antipsychotics frequently used in clinical practice.
The main limitation of this study is its naturalistic design, which may have led to the presence of nonobserved covariates that may have influenced the results. However, the naturalistic design could also be considered a strength because it reflects routine clinical practice, and so the results are likely to be more representative than those of a well-controlled trial. The heterogeneity of the sample might also be criticized, as patients with different diagnoses were included. However, this design permits a greater generalization of the results to the clinical context at these ages, in which heterogeneity of diagnosis in psychotic disorders is common. 32, 33 Heterogeneity can influence medication, although more studies are needed with larger samples and more homogeneous diagnoses to maintain the statistical power over time and to study the potential influences on treatment effectiveness, duration, and outcomes in greater detail. Another limitation is the sample size especially to compare subgroups with different antipsychotics, although our sample is larger than previous long-term studies in children and adolescents. The fact that the pharmacological assessments were performed at discrete time points may be another limitation. Possibly, a methodological design that assessed treatment duration or time to discontinuation might have provided additional information. Among the strengths of the study, we emphasize the large sample size compared with previous studies in children and adolescents and the long follow-up period. Moreover, the short period of positive psychotic symptoms before first assessment allows us to study the evolution of treatment from the onset of the disorder.
In conclusion, the rates of discontinuation in children and adolescents with a first psychotic episode are high and similar to those observed in adults. No significant differences were found in discontinuation rates between different antipsychotics. Higher rates were observed during the first year. Differences in adverse effects were found at 6 months, but not later, probably because in everyday clinical practice treatment is adjusted over time, depending on clinical response and tolerance. Clozapine showed a high maintenance rate and tolerability comparable to that of other antipsychotics more frequently used in children and adolescents.
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